

Ref: 42/SE/LC/2024-25

Date: 14/08/2024

To,

**Head, Listing Compliance Department
BSE Limited**

Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai - 400 001.

Scrip Code: 544122

**Head, Listing Compliance Department
National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai- 400051

Scrip Symbol: ENTERO

Dear Sir/Madam,

Subject: Submission of Unaudited Financial Results for quarter ended on June 30, 2024

Reference: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ("LODR")

Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at their meeting held today i.e., August 14, 2024, inter alia, considered and approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2024 and Limited Review Report on the aforesaid Unaudited Financial Results.

The said results in the prescribed format along with Limited Review Report of Statutory Auditors of the Company are enclosed herewith.

The aforesaid Unaudited Financial Results were reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company, at their respective meetings held today.

The Board Meeting commenced at 1:45 PM (IST) and concluded at 5:00 PM (IST).

This outcome and results will also be uploaded on the website of the Company.

You are requested to take the same on record.

For Entero Healthcare Solutions Limited

Jayant Prakash

General Counsel, Company Secretary & Compliance Officer

(Mem: F6742)



Entero Healthcare Solutions Limited

(formerly known as Entero Healthcare Solutions Private Limited)

Registered Office: Plot No. I-35, Building-B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003

Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Mumbai - 400051

CIN:L74999HR2018PLC072204

Tel. No.: 022-26529100

Email: info@enterohealthcare.com

Website: www.enterohealthcare.com

Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2024

(Rs. in Millions, except per equity share data)

Sr. No.	Particulars	Quarter ended		Year ended	
		30 June 2024 (Unaudited)	31 March 2024 (Refer note 3)	30 June 2023 (Unaudited) (Refer note 4)	31 March 2024 (Audited)
1	Income				
	a) Revenue from operations	1,223.84	1,065.61	612.00	3,181.61
	b) Other income	321.71	423.95	147.61	899.25
	Total Income	1,545.55	1,489.56	759.61	4,080.86
2	Expenses				
	a) Purchase of Stock-in-trade	1,273.35	980.82	539.49	2,885.03
	b) Changes in inventories of Stock-in-trade	(227.87)	(43.81)	(35.10)	(189.65)
	c) Employee benefits expense	114.89	129.89	135.87	562.46
	d) Finance costs	4.10	56.10	46.51	223.18
	e) Depreciation and amortisation expense	21.69	17.26	24.08	87.48
	f) Other expenses	81.96	90.61	47.91	268.71
	Total Expenses	1,268.12	1,230.87	758.76	3,837.21
3	Profit/(Loss) before tax (1) - (2)	277.43	258.69	0.85	243.65
4	Tax expenses				
	Current tax	38.22	-	-	-
	Deferred tax charge/(credit)	30.46	(114.10)	(22.74)	(140.75)
	Total tax expenses	68.68	(114.10)	(22.74)	(140.75)
5	Profit/(loss) for the period/year (4) - (5)	208.75	372.79	23.59	384.40
6	Other comprehensive income				
	Items that will not be reclassified subsequently to profit and loss	0.35	1.40	(0.01)	1.40
	Income tax effect on above	(0.09)	(0.35)	-	(0.35)
	Total other comprehensive income	0.26	1.05	(0.01)	1.05
7	Total comprehensive income (6) + (7)	209.01	373.84	23.58	385.45
8	Paid-up equity share capital (face value - Rs. 10 per share)	434.94	434.94	41.12	434.94
9	Other equity				15,829.19
10	Earnings per share (Face value of Rs.10 each) basic- (Rs.)*	4.80	10.19	0.69	10.63
	Earnings per share (Face value of Rs.10 each) diluted - (Rs.)*	4.80	10.19	0.69	10.63

(*not annualised for the quarters)

See accompanying notes to the unaudited standalone financial results





Entero Healthcare Solutions Limited

(formerly known as Entero Healthcare Solutions Private Limited)

Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003

Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Mumbai - 400051

CIN:L74999HR2018PLC072204

Tel. No.: 022-26529100

Email: info@enterohealthcare.com

Website: www.enterohealthcare.com

NOTES:

- 1 In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, the above unaudited standalone financial results of Entero Healthcare Solutions Limited (formerly known as Entero Healthcare Solutions Private Limited) ("the Company") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors, at their respective meetings held on 14 August 2024. These unaudited standalone financial results have been subjected to limited review by the statutory auditors of the Company and they have expressed an unmodified conclusion on these unaudited standalone financial results.
- 2 The Company operates only in one business segment i.e. trading of pharmaceutical and surgical products and hence, the Company has only one reportable segment as per Ind AS 108 "Operating Segments".
- 3 The figures for the quarter ended 31 March 2024 are the balancing figures between the audited figures for the year ended 31 March 2024 and published unaudited figures for the nine months ended 31 December 2023.
- 4 The Equity shares of the Company were listed on the BSE Limited ("BSE") and National Stock Exchanges of India Limited ("NSE") on 16 February 2024. Consequently, the requirement for submission of quarterly financial results to the stock exchanges became applicable to the Company with effect from quarter ended 31 December 2023. Hence, the Company was not required to present and prepare quarterly financial results for the quarter ended 30 June 2023, which has been prepared by the Company management.
- 5 The utilization of the proceeds (net of IPO expenses) as on 30 June 2024 is summarized as below:

Particulars	Utilisation as per prospectus	Utilisation up to 30 June 2024	Unutilised up to 30 June 2024
Repayment/prepayment in full or part, of certain borrowings availed by Company	1,425.00	1,425.00	-
Funding of long term working capital requirements of the company and its subsidiaries	4,800.00	1,799.50	3,000.50
Inorganic growth initiative through acquisitions	2,370.00	-	2,370.00
General corporate purposes	918.30	238.70	679.60
Total	9,513.30	3,463.20	6,050.10

- 6 During the quarter ended 30 June 2024, the Company has entered into a share purchase agreement with Avenir Lifecare pharma Private Limited for purchase of 8,000 equity shares at Rs 10 each (80% stake) on 7 May 2024 and Suprabhat Pharmaceutical Distributors Private Limited for purchase of 10,000 equity shares at Rs 10 each (100% stake) on 12 June 2024 respectively.
- 7 Subsequent to the quarter ended 30 June 2024, the Company has entered into share purchase agreements with the following entities, resulting the same entities becoming the subsidiary of the Company:

Name of the entity	Date of share transfer	Number of shares acquired	% of shareholding
Devi Pharma Wellness Private Limited	14-July-2024	10,000	100.00%
Gourav Medical Agencies Private Limited	09-August-2024	8,000	80.00%
Srinivasa Lifecare Private Limited	13-August-2024	7,000	70.00%

- 8 The above standalone financial results of the Company are available on the website of the Company (www.enterohealthcare.com) and on the websites of NSE (www.nseindia.com) and BSE (www.bseindia.com).
- 9 Previous year's/period's figures have been regrouped/ reclassified wherever necessary to conform to current period's classification.

Entero Healthcare Solutions Limited

Prabhat Agrawal
CEO & Managing Director
DIN: 07466382
Place: Mumbai
Date: 14 August 2024



Independent Auditor's Review Report on unaudited Standalone financial results of Entero Healthcare Solutions Limited for the quarter ended June 30, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Entero Healthcare Solutions Limited

1. We have reviewed the accompanying Statement of unaudited Standalone financial results of Entero Healthcare Solutions Limited (formerly known as Entero Healthcare Solutions Private Limited) (hereinafter referred to as 'the Company') for the quarter ended June 30, 2024 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



MSKA & Associates

Chartered Accountants

5. The Statement includes results for the quarter ended June 30, 2023, that have been approved by the Board of Directors, and have not been subjected to review or audit by us or by another auditor.

Our conclusion is not modified in respect of the above matter

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Amrish Vaidya
Membership No.:101739
UDIN: 24101739BKEZTT3827



Place: Mumbai
Date: August 14, 2024



Entero Healthcare Solutions Limited

(formerly known as Entero Healthcare Solutions Private Limited)

Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003

Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Mumbai - 400051

CIN:L74999HR2018PLC072204

Tel. No.: 022-26529100

Email: info@enterohealthcare.com

Website: www.enterohealthcare.com

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2024

(Rs. in Millions, except per equity share data)

Sr. No.	Particulars	Quarter ended		Year ended	
		30 June 24 (Unaudited)	31 March 2024 (Refer note 3)	30 June 2023 (Unaudited) (Refer note 4)	31 March 2024 (Audited)
1	Income				
	a) Revenue from operations	10,970.36	10,341.76	8,991.97	39,223.10
	b) Other income	134.36	91.49	13.98	144.13
	Total Income	11,104.72	10,433.25	9,005.95	39,367.23
2	Expenses				
	a) Purchase of Stock-in-trade	10,696.72	9,560.42	8,309.75	36,278.08
	b) Changes in inventories of Stock-in-trade	(726.04)	(144.75)	(112.69)	(574.55)
	c) Employee benefits expense	435.67	379.35	360.32	1,511.46
	d) Finance costs	97.04	173.23	143.90	656.84
	e) Depreciation and amortisation expense	66.06	71.44	59.47	250.17
	f) Other expenses	262.28	257.96	176.65	889.68
	Total Expenses	10,831.73	10,297.65	8,937.39	39,011.68
3	Profit/(Loss) before tax (1) - (2)	272.99	135.60	68.55	355.55
4	Tax expenses				
	Current tax	61.56	51.28	29.10	133.78
	Deferred tax charge/(credit)	6.13	(127.44)	(24.84)	(176.22)
	Total tax expenses	67.69	(76.16)	4.26	(42.44)
5	Profit/(Loss) for the year/year (3) -(4)	205.30	211.76	64.29	397.99
6	Other comprehensive income				
	Items that will not be reclassified subsequently to profit and loss	(0.47)	(2.10)	(0.01)	(2.58)
	Income tax effect on above	0.12	0.41	-	0.41
	Total other comprehensive income	(0.35)	(1.69)	(0.01)	(2.17)
7	Total comprehensive income (5) + (6)	204.95	210.07	64.28	395.82
8	Profit/(Loss) attributable to:				
	Owners of the Company	200.80	209.67	62.40	391.09
	Non-controlling interest	4.50	2.09	1.89	6.90
9	Other comprehensive income attributable to:				
	Owners of the Company	(0.35)	(1.69)	(0.01)	(2.17)
	Non-controlling interest	-	(0.00)	-	(0.00)
10	Total comprehensive income attributable to:				
	Owners of the Company	200.45	207.98	62.40	388.92
	Non-controlling interest	4.50	2.09	1.89	6.90
11	Paid-up equity share capital (face value - Rs. 10 per share)	434.94	434.94	41.12	434.94
12	Other equity				15,945.62
13	Earnings per share (Face value of Rs.10 each) basic- (Rs.)*	4.62	5.73	1.82	10.81
	Earnings per share (Face value of Rs.10 each) diluted - (Rs.)*	4.62	5.73	1.82	10.81

(*not annualised for the quarters)

See accompanying notes to the unaudited consolidated financial results





Entero Healthcare Solutions Limited

(formerly known as Entero Healthcare Solutions Private Limited)

Registered Office: Plot No. I-35, Building -B, Industrial Area Phase-I, 13/7 Mathura Road, Faridabad, Haryana, 121003

Corporate Office: Unit No. 605 & 606, 6th Floor, Trade Centre, Bandra Kurla Complex, Mumbai - 400051

CIN:L74999HR2018PLC072204

Tel. No.: 022-26529100

Email: info@enterohealthcare.com

Website: www.enterohealthcare.com

NOTES:

- 1 In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, the above unaudited consolidated financial results of Entero Healthcare Solutions Limited (formerly known as Entero Healthcare Solutions Private Limited) ("the Holding Company" or "the Company"), and its subsidiaries (the Holding Company along with subsidiaries together referred to as "the Group") have been reviewed and recommended by the Audit Committee and approved by the Board of Directors, at their respective meetings held on 14 August 2024. These unaudited consolidated financial results have been subjected to limited review by the statutory auditors of the Company and they have expressed an unmodified conclusion on these unaudited consolidated financial results.
- 2 The Group operates only in one business segment i.e. trading of pharmaceutical and surgical products and hence, the Group has only one reportable segment as per Ind AS 108 "Operating Segments".
- 3 The figures for the quarter ended 31 March 2024 are the balancing figures between the audited figures for the year ended 31 March 2024 and published unaudited figures for the nine month ended 31 December 2023.
- 4 The Equity shares of the Holding Company were listed on the BSE Limited ("BSE") and National Stock Exchanges of India Limited ("NSE") on 16 February 2024. Consequently, the requirement for submission of quarterly financial results to the stock exchanges became applicable to the Holding Company with effect from quarter ended 31 December 2023. Hence, the Holding Company was not required to present and prepare quarterly financial results for the quarter ended 30 June 2023, which has been prepared by the Holding Company management.
- 5 The utilization of the proceeds (net of IPO expenses) as on 30 June 2024 is summarized as below:

Particulars	Utilisation as per prospectus	Utilisation up to 30 June 2024	Unutilised up to 30 June 2024
Repayment/prepayment in full or part, of certain borrowings availed by Company	1,425.00	1,425.00	-
Funding of long term working capital requirements of the Company and its subsidiaries	4,800.00	1,799.50	3,000.50
Inorganic growth initiative through acquisitions	2,370.00	-	2,370.00
General corporate purposes	918.30	238.70	679.60
Total	9,513.30	3,463.20	6,050.10

- 6 During the Quarter ended 30 June 2024, the Holding Company has entered into a share purchase agreement with Avenir Lifecare pharma Private Limited for purchase of 8000 equity shares at Rs 10 each (80% stake) on 7 May 2024 and Suprabhat Pharmaceutical Distributors Private Limited for purchase of 10000 equity shares at Rs 10 each (100% stake) on 12 June 2024. The Holding Company has accounted both acquisitions as per Ind AS 103- 'Business Combinations', on provisional basis in the consolidated financial results. The Holding Company expects it to be finalised within a period of one year from the date of acquisition. The figures for the quarter ended 30 June 2024 includes figures of the aforesaid acquired entities from the period 7 May 2024 to 30 June 2024 and 12 June 2024 to 30 June 2024, respectively, and are not comparable with the corresponding/ comparative period.
- 7 Subsequent to the quarter ended 30 June 2024, the Holding Company has entered into share purchase agreements with the following entities, resulting the same entities becoming the subsidiary of the Holding Company:

Name of the entity	Date of share transfer	Number of shares acquired	% of shareholding
Devi Pharma Wellness Private Limited	14-July-2024	10,000	100.00%
Gourav Medical Agencies Private Limited	09-August-2024	8,000	80.00%
Srinivasa Lifecare Private Limited	13-August-2024	7,000	70.00%

- 8 The above consolidated financial results of the Holding Company are available on the website of the Holding Company (www.enterohealthcare.com) and on the websites of NSE (www.nseindia.com) and BSE(www.bseindia.com).
- 9 Previous year's/period's figures have been regrouped/reclassified wherever necessary to conform to current period's classification.

Entero Healthcare Solutions Limited

Prabhat Agrawal
CEO & Managing Director
DIN: 07466382
Place: Mumbai
Date: 14 August 2024



Independent Auditor's Review Report on unaudited consolidated financial results of Entero Healthcare Solutions Limited for the quarter ended June 30, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Entero Healthcare Solutions Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Entero Healthcare Solutions Limited (formerly known as Entero Healthcare Solutions Private Limited) (hereinafter referred to as 'the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended June 30, 2024, ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the entities listed in Annexure 1.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of other independent auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



MSKA & Associates

Chartered Accountants

6. We did not review the interim financial results of four subsidiaries included in the Statement, whose interim financial results (before consolidation adjustments) reflects total revenues of Rs.1,258.93 million, total net (loss) after tax of Rs. (7.06) million and total comprehensive income of Rs. (7.06) million, for the quarter ended June 30, 2024, as considered in the Statement. These interim financial results have been reviewed by other auditors, whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors.


7. The Statement includes the interim financial results of twenty one subsidiaries which have not been reviewed by their auditors and are not subject to review, whose interim financial results (before consolidation adjustments) reflects total revenue of Rs.1,603.45 million, total net profit/(loss) after tax of Rs. (8.81) million and total comprehensive income of Rs. (8.81) million for the quarter ended June 30, 2024, as considered in the Statement. These interim financial results have been furnished to us by the Management and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such management prepared unaudited interim financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of the above matter with respect to our reliance on the financial result certified by the management.

8. The Statement includes results for the quarter ended June 30, 2023, that have been approved by the Board of Directors, and have not been subjected to review or audit by us or by another auditor.

Our conclusion is not modified in respect of the above matter.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Partner

Membership No.: 101739

UDIN: 24101739BKE ZTU2880



Place: Mumbai

Date: August 14, 2024

Annexure I to the Independent Auditor's Review Report on unaudited consolidated financial results of Entero Healthcare Solutions Limited for the quarter ended June 30, 2024 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Novacare Healthcare Solutions Private Limited	Subsidiary
2	R S M Pharma Private Limited	Subsidiary
3	Avenues Pharma Distributors Private Limited	Subsidiary
4	Chirag Medicare Solutions Private Limited	Subsidiary
5	Chethana Pharma Private Limited	Subsidiary
6	Jaggi Enterprises Private Limited	Subsidiary
7	Vasavi Medicare Solutions Private Limited	Subsidiary
8	SVMED Solutions Private Limited	Subsidiary
9	Millennium Medisolutions Private Limited	Subsidiary
10	G.S. Pharmaceutical Distributors Private Limited	Subsidiary
11	Getwell Medicare Solutions Private Limited	Subsidiary
12	Galaxystar Pharma Distributors Private Limited	Subsidiary
13	Barros Enterprises Private Limited	Subsidiary
14	Sesha Balajee Medisolutions Private Limited	Subsidiary
15	Rada Medisolutions Private Limited	Subsidiary
16	Sri Parshva Pharma Distributors Private Limited	Subsidiary
17	Sri Rama Pharmaceutical Distributors Private Limited	Subsidiary
18	Western Healthcare Solutions Private Limited	Subsidiary
19	Chhabra Healthcare Solutions Private Limited	Subsidiary
20	Chethana Healthcare Solutions Private Limited	Subsidiary
21	S.S. Pharma Traders Private Limited	Subsidiary
22	Sundarlal Pharma Distributors Private Limited	Subsidiary



MSKA & Associates

Chartered Accountants

23	New Siva Agencies Private Limited	Subsidiary
24	Saurashtra Medisolutions Private Limited	Subsidiary
25	New RRPD Private Limited	Subsidiary
26	Sree Venkateshwara Medisolutions Private Limited	Subsidiary
27	SVS Lifesciences Private Limited	Subsidiary
28	Swami Medisolutions Pvt Ltd	Subsidiary
29	Atreja Healthcare Solutions Private Limited	Subsidiary
30	CPD Pharma Private Limited	Subsidiary
31	Calcutta Medisolutions Private Limited	Subsidiary
32	Chethana Pharma Distributors Private Limited	Subsidiary
33	City Pharma Distributors Private Limited	Subsidiary
34	Curever Pharma Private Limited	Subsidiary
35	Rimedio Pharma Private Limited	Subsidiary
36	Quomed Life Sciences Private Limited	Subsidiary
37	Zennx Software Solutions Private Limited	Subsidiary
38	Entero R.S. Enterprises Private Limited (w.e.f. September 16, 2023)	Subsidiary
39	Dhanvanthri Super Speciality Private Limited (w.e.f. December 11, 2023)	Subsidiary
40	Avenir Lifecare Pharma Private Limited w.e.f. May 7, 2024	Subsidiary
41	Suprabhat Pharmaceuticals Private Limited w.e.f. June 12, 2024	Subsidiary

